Aytu BioPharma, Inc. Reports Net Loss of $2.5 Million for Q4 2023

Aytu BioPharma, Inc.(AYTU) has released its financial results for the fourth quarter and fiscal year ending June 30, 2023. The company's consolidated statement of operations reveals a net loss of $2.5 million for the quarter, marking a significant improvement from the net loss of $16.1 million reported for the same period in the previous year. Additionally, Aytu BioPharma reported robust revenue growth, with net product revenue surpassing the $30 million mark for the quarter, compared to $27.4 million in the same period last year.

A Positive Turnaround in Net Loss

Gross Profit Shows Significant Improvement

The company's gross profit for the quarter stood at $18.6 million, reflecting a substantial increase from $14.8 million in the previous year's fourth quarter. This improvement can be attributed to increased product revenue and effective cost management.